Specifications
- Purity
- ≥97% (NMR)
- Appearance
- Light yellow powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (10 mg/ml), water (5 mg/ml)
Documentation
- Safety Data Sheet (SDS)
- CDX M0189 MSDS.pdf
Available from stock
Moxifloxacin hydrochloride
- SKU
- M0189
Category: Antibiotics
- Synonyms
- BAY 12-8039 , Alelox , 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- 186826-86-8
- CAS-Number
- C21H24FN3O4· HCl
- Molecular Formula
- 401.43 . 36.46
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- +4°C
- Long Term Storage
- -20°C
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at -20°C.
- Transportation
- Not dangerous goods
- Description
- Moxifloxacin is a fourth-generation synthetic broad-spectrum fluoroquinolone antibiotic. It is used against both Gram-positive and Gram-negative bacteria and to treat bacterial infections associated with bronchitis, sinusitis, and other conditions. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase (Topo II) and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Can also be used as reference compound.
- Smiles
- O=C1C(C(O)=O)=CN(C2CC2)C3=C(OC)C([NH+]4C[C@](NCCC5)([H])[C@]5([H])C4)=C(F)C=C31.[Cl-]
- InChi Key
- IDIIJJHBXUESQI-DFIJPDEKSA-N
- References
- (1) M. Souli, et al., Int. J. Antimicrob. Agents. 10, 23 (1998) , (2) C. Ballow, et al., Clin. Ther. 21, 513 (1999) , (3) A. Dalhoff, et al., Clin. Infect. Dis. 32, S22 (2001) , (4) R. Kishii, et al., Antimicrob. Agents Chemother. 47, 77 (2003) , (5) M. Miravitlles, J. Chron. Obstruct. Pulmon. Dis. 2, 191 (2007) , (6) M. Miravitlles & A. Anzueto, Expert Opin. Pharmacother. 9, 1755 (2008) (Review) , (7) H. Takiff & E. Guerrero, Antimicrob. Agents Chemother. 55, 5421 (2011) , (8) M.M. Al Omari, et al., Profiles Drug Subst. Excip. Relat. Methodol. 39, 299 (2014) (Review)
- InChi
- InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24 , /h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28) , 1H/t11-,16+ , /m0./s1
Moxifloxacin is a fourth-generation synthetic broad-spectrum fluoroquinolone antibiotic. It is used against both Gram-positive and Gram-negative bacteria and to treat bacterial infections associated with bronchitis, sinusitis, and other conditions. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase (Topo II) and topoisomerase IV by binding to the enzyme-DNA complex. Compared to mammalian DNA gyrase, moxifloxacin has 100 times higher affinity for bacterial DNA gyrase. Can also be used as reference compound.
Additional information
| Synonyms | BAY 12-8039, Alelox, 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydropyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride |
|---|---|
| Purity | ≥97% (NMR) |
| Appearance | Light yellow powder |
| CAS-Number | 186826-86-8 |
| Molecular Formula | C21H24FN3O4· HCl |
| Molecular Weight | 401.43 . 36.46 |
| Identity | 1H-NMR |
| Solvents | DMSO (10 mg/ml), water (5 mg/ml) |
| Smiles | O=C1C(C(O)=O)=CN(C2CC2)C3=C(OC)C([NH+]4C[C@](NCCC5)([H])[C@]5([H])C4)=C(F)C=C31.[Cl-] |
| InChi Key | IDIIJJHBXUESQI-DFIJPDEKSA-N |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Transportation | Not dangerous goods |
| References | (1) M. Souli, et al., Int. J. Antimicrob. Agents. 10, 23 (1998), (2) C. Ballow, et al., Clin. Ther. 21, 513 (1999), (3) A. Dalhoff, et al., Clin. Infect. Dis. 32, S22 (2001), (4) R. Kishii, et al., Antimicrob. Agents Chemother. 47, 77 (2003), (5) M. Miravitlles, J. Chron. Obstruct. Pulmon. Dis. 2, 191 (2007), (6) M. Miravitlles & A. Anzueto, Expert Opin. Pharmacother. 9, 1755 (2008) (Review), (7) H. Takiff & E. Guerrero, Antimicrob. Agents Chemother. 55, 5421 (2011), (8) M.M. Al Omari, et al., Profiles Drug Subst. Excip. Relat. Methodol. 39, 299 (2014) (Review) |
| InChi | InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24, /h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28), 1H/t11-,16+, /m0./s1 |
| Quantity | 50 mg, Bulk |
